OTCMKTS:NEXI NexImmune Earnings Date & Estimates NexImmune is estimated to report earnings on Tuesday, November 17, 2026. Research:Profile Upcoming Earnings Announcement Announcement DateNovember 17, 2026 Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from NexImmuneNexImmune is expected to post earnings of -$13.25 per share. NexImmune has beaten the consensus EPS estimate in 5 of its last 8 quarters.Consensus EstimatesConsensus EPS-$13.25Recent Track RecordLast ReportedQ2 2024Last Quarter EPS-$1.69EPS Beat Rate5 of last 8 quartersPrepare for the Earnings CallCompany ProfileQ2 2024 Earnings ReportQ1 2024 Earnings ReportQ4 2023 Earnings Report NexImmune Earnings FAQ When does NexImmune report earnings? NexImmune (OTCMKTS:NEXI) is estimated to report earnings on Tuesday, November 17, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What is the consensus EPS estimate for NexImmune? Analysts expect NexImmune to post earnings of -$13.25 per share for the quarter. NexImmune Earnings HeadlinesItalian state investor CDP to raise stake in payments group NexiMay 25, 2026 | reuters.comShattuck Labs stock craters following pipeline and job cutsOctober 2, 2024 | msn.comThe warning signs most investors see too lateDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008.November 10 at 1:00 AM | Weiss Ratings (Ad)NexImmune moves forward with wind-down processAugust 31, 2024 | bizjournals.comNexImmune adjourns special meeting to explore optionsAugust 4, 2024 | investing.comNEXI Stock Alert: NexImmune Delists From NasdaqJuly 12, 2024 | investorplace.comSee More NexImmune Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NexImmune? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NexImmune and other key companies, straight to your email. Email Address About NexImmuneNexImmune (OTCMKTS:NEXI) was a biotechnology company focused on developing cell-based immunotherapies for cancer. Its Artificial Immune Modulation (AIM) platform was designed to activate and expand T cells that recognize specific cancer-associated targets. The company’s investigational programs included NEXI-001, a T-cell therapy for acute myeloid leukemia, and NEXI-002, a program for multiple myeloma. NexImmune was based in Gaithersburg, Maryland, and its therapies were in clinical development rather than commercially available. NexImmune later discontinued operations and filed for Chapter 7 bankruptcy in 2023. Its programs should therefore be understood as historical development efforts, not as an indication of current commercial services.View NexImmune ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
